American Journal of Cardiovascular Drugs

, Volume 12, Issue 1, pp 7–22 | Cite as

Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus

Implications of the Results of Recent Clinical Trials in Type 2 Diabetes
  • Nikhil Tandon
  • Mohammed K. Ali
  • K. M. Venkat Narayan
Review Article

Abstract

Observational epidemiologic data indicate that lower blood glucose levels, blood pressure (BP), and lipid parameters are associated with a lower incidence of micro- and macrovascular complications in people with diabetes. While no threshold for this effect is discernible in these observational studies, intervention studies do not mirror this finding. The earliest glycemia target study in type 2 diabetes mellitus, UKPDS, demonstrated unequivocal benefits of tight glucose control on microvascular complications, but needed a prolonged follow-up to demonstrate a benefit on macrovascular outcomes and mortality. Recently, three major studies, ACCORD, ADVANCE, and VADT, evaluated the impact of attaining euglycemia (ACCORD) or near-euglycemia (ADVANCE, VADT) in older patients with diabetes and high cardiovascular (CV) risk. None of these studies, either individually or on pooled analysis, demonstrated any reduction in all-cause or CV mortality, although the meta-analyses revealed 15–17% reductions in the incidence of non-fatal myocardial infarction in those exposed to tight glucose control. A higher mortality was observed in the intensive glucose control arm of ACCORD, resulting in the premature termination of the glucose-lowering component of this study. Also, the occurrence of hypoglycemic episodes (total and major) was significantly higher in the intensive glucose control arm.

ADVANCE and ACCORD also had BP-lowering components. While data from ADVANCE demonstrated a benefit of routine use of a combination of perindopril and indapamide, with a decline in all-cause mortality, CV mortality, and new-onset microalbuminuria, reducing systolic BP to <120 mmHg in ACCORD did not result in any incremental benefits over a systolic BP <140 mmHg.

A residual CV risk observed in people with diabetes even after low-density lipoprotein (LDL) cholesterol lowering has led to trials evaluating additional therapy with fibric acid derivatives to reduce triglyceride levels. The lipid-lowering arm of ACCORD failed to demonstrate any benefit of add-on therapy with fibric acid derivatives to LDL-lowering treatment with HMG-CoA reductase inhibitors (statins) on vascular outcomes in patients with diabetes. However, data from earlier studies, and also from the subgroup analysis of ACCORD, indicate a probable benefit of adding treatment with fibric acid derivatives to individuals with persistently elevated triglyceride levels despite statin therapy.

The most compelling evidence comes from studies assessing the impact of multiple risk factors — glucose, BP, and cholesterol. Studies like the Steno study unequivocally demonstrate the benefit of aggressive control of all three parameters on vascular outcomes in patients with diabetes.

In conclusion, attempts to achieve euglycemia in older patients with type 2 diabetes with co-morbidities are not associated with any survival benefit, but may reduce the occurrence of non-fatal CV events. There is a significant risk of major hypoglycemia with this approach, thereby probably limiting its utility to younger patients with new-onset disease. Similarly, lowering systolic BP below 120 mmHg in high CV risk people with diabetes is associated with significant excess adverse events, limiting the utility of such an intervention. However, a clear benefit, which is also cost effective, is observed with strategies for multiple risk-factor control, which should be universally adopted in clinical practice.

Keywords

Blood Pressure Control Fibric Acid Derivative Tight Glucose Control Intensive Glucose Control Tight Blood Pressure Control 

Notes

Acknowledgments

Nikhil Tandon was National Co-Principal Investigator (India), Site Principal Investigator and Glucose Control Consultant (India) for ADVANCE. M.K. Ali is part of a post hoc writing group evaluating cost and health-related quality of life for the ACCORD trial. K.M. Venkat Narayan was previously a member of the Executive Committee and Committee of Investigators for the ACCORD trial.

The views expressed by the authors in this manuscript are personal and are entirely based on published information.

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Stratton IM, Adler AI, Haw N, et al. UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. BMJ 2000; 321: 405–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr CV mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421–31.PubMedGoogle Scholar
  5. 5.
    Sarwar N, Aspelund T, Eiriksdottir G, et al. Markers of dysglycemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 2010; 7: e1000728.Google Scholar
  6. 6.
    Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 27–38.PubMedCrossRefGoogle Scholar
  8. 8.
    The DECODE study Group on behalf of the European Diabetes Epidemiology Group. Is the current definition of diabetes relevant to mortality risk from all causes and cardiovascular and non-cardiovascular diseases. Diabetes Care 2003; 26: 688–96.CrossRefGoogle Scholar
  9. 9.
    Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004; 27: 2836–42.CrossRefGoogle Scholar
  10. 10.
    Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition. BMJ 2001; 322: 15–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Gerstein HC, Pogue J, Mann JFE, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749–55.PubMedCrossRefGoogle Scholar
  12. 12.
    The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet 2010; 375: 2215–22.CrossRefGoogle Scholar
  13. 13.
    Juutilainen A, Lehto S, Rönnemaa T, et al. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008; 31: 714–9.PubMedCrossRefGoogle Scholar
  14. 14.
    The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.CrossRefGoogle Scholar
  15. 15.
    ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.CrossRefGoogle Scholar
  16. 16.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.CrossRefGoogle Scholar
  17. 17.
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.CrossRefGoogle Scholar
  18. 18.
    Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39.PubMedCrossRefGoogle Scholar
  19. 19.
    Ismail-Begi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet 2010; 376: 419–30.CrossRefGoogle Scholar
  20. 20.
    Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Anderson RT, Venkat Narayan KM, Feeney P, et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes. Diabetes Care 2011; 34: 807–12.PubMedCrossRefGoogle Scholar
  22. 22.
    The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818–28.CrossRefGoogle Scholar
  23. 23.
    Beulens JWJ, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009; 52: 2027–36.PubMedCrossRefGoogle Scholar
  24. 24.
    Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.PubMedCrossRefGoogle Scholar
  25. 25.
    The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease. N Engl J Med 2005; 353: 2643–53.CrossRefGoogle Scholar
  26. 26.
    The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233–44.CrossRefGoogle Scholar
  27. 27.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.CrossRefGoogle Scholar
  28. 28.
    Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009; 373: 1766–72.CrossRefGoogle Scholar
  29. 29.
    Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008; 24: 353–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2009; 339: b4909. doi: 10.1136/bmj.b4909.Google Scholar
  31. 31.
    Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2009; 339: b5444. doi: 10.1136/bmj. b5444.Google Scholar
  32. 32.
    Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010; 160: 8–19.PubMedCrossRefGoogle Scholar
  34. 34.
    Nathan DM. The role of glycemia management in the prevention of cardiovascular disease — starting over? Ann Intern Med 2009; 151: 888–9.PubMedGoogle Scholar
  35. 35.
    Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 2009; 151: 854–60.PubMedGoogle Scholar
  36. 36.
    Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–98.PubMedCrossRefGoogle Scholar
  37. 37.
    Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394–403.PubMedGoogle Scholar
  38. 38.
    Ma J, Yang W, Fang N, et al. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a metaanalysis. Nutr Metab Cardiovasc Dis 2009; 19: 596–603.PubMedCrossRefGoogle Scholar
  39. 39.
    Mannucci E, Monami M, Lamanna C, et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604–12.PubMedCrossRefGoogle Scholar
  40. 40.
    Marso SP, Kennedy KF, House JA, et al. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and metaanalysis. Diab Vasc Dis Res 2010; 7: 119–30.PubMedCrossRefGoogle Scholar
  41. 41.
    The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575–85.CrossRefGoogle Scholar
  42. 42.
    ADVANCE Collaborative group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.CrossRefGoogle Scholar
  43. 43.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS. BMJ 1998; 317: 703–13.CrossRefGoogle Scholar
  44. 44.
    Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565–76.PubMedCrossRefGoogle Scholar
  45. 45.
    Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertension 2006; 24: 1201–8.CrossRefGoogle Scholar
  46. 46.
    Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial study. J Hypertension 2009; 27: 1360–9.CrossRefGoogle Scholar
  47. 47.
    Law MR, Morris K, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665. doi:10.1136/bmj.b1665.PubMedCrossRefGoogle Scholar
  48. 48.
    Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidemia and hyperlipidemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16.CrossRefGoogle Scholar
  50. 50.
    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multi-centre, randomised placebo-controlled trial. Lancet 2004; 364: 685–96.PubMedCrossRefGoogle Scholar
  51. 51.
    Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterollowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117–25.CrossRefGoogle Scholar
  52. 52.
    Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.Google Scholar
  53. 53.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001–9.PubMedCrossRefGoogle Scholar
  54. 54.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57.CrossRefGoogle Scholar
  55. 55.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45.PubMedCrossRefGoogle Scholar
  56. 56.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–8.PubMedCrossRefGoogle Scholar
  57. 57.
    The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563–74.CrossRefGoogle Scholar
  58. 58.
    Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37–45.PubMedCrossRefGoogle Scholar
  59. 59.
    The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21–7.CrossRefGoogle Scholar
  60. 60.
    Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Gaede P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–91.PubMedCrossRefGoogle Scholar
  64. 64.
    Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Zoungas S, De Galan BE, Ninomiya T, et al. Combined effect of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes. Diabetes Care 2009; 32: 2068–74.PubMedCrossRefGoogle Scholar
  66. 66.
    Gaede P, Valentine WJ, Palmer AJ, et al. Cost effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes. Diabetes Care 2008; 31: 1510–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Clarke PM, Gray AM, Briggs A, et al. Cost utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005; 48: 868–77.PubMedCrossRefGoogle Scholar
  68. 68.
    Currie CC, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Gerstein HC. More insights on the dysglycaemia-cardiovascular connection. Lancet 2010; 375:2195–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53: 2079–85.PubMedCrossRefGoogle Scholar
  71. 71.
    Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122: 847–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Lauritzen T, Griffin S, Borch-Johnsen K, et al. Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000 Sep; 24 Suppl. 3: S6–11.Google Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Nikhil Tandon
    • 1
  • Mohammed K. Ali
    • 2
  • K. M. Venkat Narayan
    • 2
  1. 1.Department of Endocrinology and MetabolismAll India Institute of Medical SciencesAnsari Nagar, New DelhiIndia
  2. 2.Rollins School of Public HealthEmory UniversityAtlantaUSA

Personalised recommendations